	Application No.	Applicant(s)
Madia E A II - 1 1114	10/075,429	MARTANI, ROSA
Notice of Allowability	Examiner	Art Unit
	Susan T. Tran	1615
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to Examiner's Amendment filed 09/08/06.		
2. The allowed claim(s) is/are <u>1-6,8,9 and 27.</u>		
 3. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some* c) None of the: 1. Certified copies of the priority documents have been received. 		
2. Certified copies of the priority documents have been received in Application No		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) hereto or 2) to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s) 1. Notice of References Cited (PTO-892)	5. ☐ Notice of Informal Pa	otant Application
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. ⊠ Interview Summary	• •
_	Paper No./Mail Date	e <u>09/08/06</u> .
3. Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date	7. ⊠ Examiner's Amendm	
 Examiner's Comment Regarding Requirement for Deposit of Biological Material 	8. 🛛 Examiner's Stateme	nt of Reasons for Allowance
- -	9.	

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Edward J. Wilusz, Jr. on 09/08/06.

The application has been amended as follows:

Claim 1, last line, after the word "respectively", the phrase "wherein the manufactured solid pharmaceutical or veterinary dosage form for oral administration is in the form of a tablet, and wherein in step (c) the suitable amount of the powder or granulated which is subjected to compaction contains an intended dose of the active substance" has been inserted.

Claims 7, 10 and 11 have been cancelled.

Claim 27, last line, after the phrase "substance are placed therein", the phrase "wherein the manufactured solid pharmaceutical dosage form is for oral administration in a form of a tablet, and wherein in step (b) the suitable amount of the powder or granulated which is subjected to compaction contains an intended dose of the active substance" has been inserted.

The following is an examiner's statement of reasons for allowance:

Page 3

The closest prior art, Humbert-Droz, does not teach compacting a powder or granulate containing an intended dose of active substance, placing the compacted powder or granulate in a mold in combination with a solvent, which solvent evaporated and produce a tablet dosage form for oral administration. Humbert-Droz, in contrast, teaches all of the ingredients are dissolved or suspended in a solvent first, and the solution or suspension is placed in a mold and the solvent is then evaporated leaving a solid mass in the mold. Humbert-Droz teaches the process without applying any compression force (the compacting step) (page 5, 3rd paragraph).

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Claims 1-6, 8, 9 and 27 are allowed.

Correspondence

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Susan T. Tran whose telephone number is (571) 272-0606. The examiner can normally be reached on M-F 6:00 am to 4:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Woodward can be reached on (571) 272-8373. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/075,429 Page 4

Art Unit: 1615

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

S. Tran

Primary Examiner

pm

Art Unit 1615